Format

Send to

Choose Destination
Urol Oncol. 2014 May;32(4):391-5. doi: 10.1016/j.urolonc.2013.11.003. Epub 2014 Feb 6.

Why is perioperative chemotherapy for bladder cancer underutilized?

Author information

1
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
2
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada. Electronic address: boothc@kgh.kari.net.

Abstract

Despite clinical evidence and recommendations from international treatment guidelines, the use of perioperative chemotherapy for muscle-invasive bladder cancer in routine practice remains low. Although multiple studies have described underutilization, there is an urgent need to better understand the elements contributing to the observed gaps in care. In this commentary, we explore what is known about the factors contributing to underutilization of perioperative chemotherapy for muscle-invasive bladder cancer. We also propose a framework to guide future knowledge translation activities in an effort to improve the care and outcomes of patients with this disease.

KEYWORDS:

bladder cancer; chemotherapy; health policy; knowledge translation; medical decision making; practice patterns; quality of care

PMID:
24508282
DOI:
10.1016/j.urolonc.2013.11.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center